Comparison of a Single RTX-GRT7039 and Placebo Intra-articular Injection for Pain Associated With Osteoarthritis of the Knee

NCT ID: NCT05449132

Last Updated: 2025-03-21

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE3

Total Enrollment

450 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-26

Study Completion Date

2024-08-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of RTX-GRT7039 versus placebo in patients who have pain associated with osteoarthritis of the knee despite standard of care.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This trial comprises a total observation period of up to 52 weeks.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Osteoarthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

RTX-GRT7039

Participants will receive a intra-articular injection of RTX-GRT7039 during the 52-week double-blind treatment period.

Group Type EXPERIMENTAL

RTX-GRT7039

Intervention Type DRUG

RTX-GRT7039 intra-articular injection.

Placebo

Participants will receive a intra-articular injection of placebo matching RTX-GRT7039 during the 52-week double-blind treatment period.

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type DRUG

Placebo matching RTX-GRT7039 intra-articular injection.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

RTX-GRT7039

RTX-GRT7039 intra-articular injection.

Intervention Type DRUG

Placebo

Placebo matching RTX-GRT7039 intra-articular injection.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* The participant has given written informed consent to participate.
* The participant is 18 years of age or older at the Screening Visit.
* The participant has a diagnosis of osteoarthritis of the knee based on American College of Rheumatology criteria and functional capacity class of I to III.
* There is a documented history indicating that participant has insufficient pain relief with previous Standard of Care.

Exclusion Criteria

* The participant has past joint replacement surgery of the index knee.
* The participant has a history of significant trauma or surgery (e.g., open or arthroscopic) to the index knee within 12 months of Screening.
* The participant has periarticular pain from any cause other than osteoarthritis, including referred pain, bursitis, or tendonitis.
* The participant has clinical hip osteoarthritis on the side of the index knee.
* The participant has pre-existing osteonecrosis, subchondral insufficiency fracture, atrophic osteoarthritis, severe bone on bone osteoarthritis, knee pain attributable to disease other than osteoarthritis, or the participant has rapidly progressing osteoarthritis (RPOA) Type I or Type II.
* The participant has significant malalignment of anatomical axis (medial angle formed by the femur and tibia) of the target knee (varus \>10, valgus \>10) by X-ray as assessed by independent Central Readers at Screening Visit.
* The participant has other conditions that could affect trial endpoint assessments of the index knee.
* The participant has current clinically significant disease(s) or condition(s) that may affect efficacy or safety assessments, or any other reason which, in the investigator's opinion, may preclude the participant's participation in the full duration of the trial.
* The participant has a history of hypersensitivity to resiniferatoxin (RTX) or any similar component (capsaicin, chili peppers).
* The participant is currently participating or was participating in another investigational drug trial within 3 months prior to the Screening Visit.
* The participant is an employee of the investigator or trial site, with direct involvement in the proposed trial or other trials under the direction of that investigator or trial site or is a family member of the employees or the investigator.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Grünenthal GmbH

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Achieve Clinical Research, LLC

Birmingham, Alabama, United States

Site Status

Arizona Arthritis and Rheumatology Associates (AARA) P.C

Glendale, Arizona, United States

Site Status

Elite Clinical Studies, LLC

Phoenix, Arizona, United States

Site Status

Noble Clinical Research

Tucson, Arizona, United States

Site Status

Tucson Orthopaedic Research Center

Tucson, Arizona, United States

Site Status

Orange County Research Institute

Anaheim, California, United States

Site Status

Core Health Care Group

Cerritos, California, United States

Site Status

Acclaim Clinical Research, Inc.

San Diego, California, United States

Site Status

Dr. Hans Richard Barthel, MD Office Of

Santa Barbara, California, United States

Site Status

Medvin Clinical Research

Thousand Oaks, California, United States

Site Status

Westlake Medical Research

Thousand Oaks, California, United States

Site Status

Allied Biomedical Research Institute

Miami, Florida, United States

Site Status

Well Pharma Medical Research, Corp.

Miami, Florida, United States

Site Status

Sensible Healthcare LLC

Ocoee, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc. dba CNS Healthcare

Orlando, Florida, United States

Site Status

Clinical Neuroscience Solutions, Inc.

Orlando, Florida, United States

Site Status

Progressive Medical Research

Port Orange, Florida, United States

Site Status

Gulfcoast Research Institute

Sarasota, Florida, United States

Site Status

Better Health Clinical Research, Inc.

Newnan, Georgia, United States

Site Status

Vista Clinical Research

Newnan, Georgia, United States

Site Status

North Georgia Clinical Research

Woodstock, Georgia, United States

Site Status

Injury Care Research

Boise, Idaho, United States

Site Status

Chicago Clinical Research Institute Inc.

Chicago, Illinois, United States

Site Status

Chicago Medical Research, LLC

Hazel Crest, Illinois, United States

Site Status

MediSphere Medical Research Center, LLC

Evansville, Indiana, United States

Site Status

Neuroscience Research Center, LLC

Overland Park, Kansas, United States

Site Status

DelRicht Research

New Orleans, Louisiana, United States

Site Status

LCMC Health Urgent Care - Lakeview

New Orleans, Louisiana, United States

Site Status

June DO,PC

Lansing, Michigan, United States

Site Status

Oakland Medical Research Center

Troy, Michigan, United States

Site Status

Sundance Clinical Research, LLC

St Louis, Missouri, United States

Site Status

Excel Clinical Research

Las Vegas, Nevada, United States

Site Status

Las Vegas Clinical Trials, LLC

North Las Vegas, Nevada, United States

Site Status

Albuquerque Clinical Trials, Inc.

Albuquerque, New Mexico, United States

Site Status

Drug Trials America

Hartsdale, New York, United States

Site Status

Upstate Clinical Research Associates

Williamsville, New York, United States

Site Status

Accellacare Research of Charlotte

Charlotte, North Carolina, United States

Site Status

Park Road Medical Clinic

Charlotte, North Carolina, United States

Site Status

Accellacare of Raleigh

Raleigh, North Carolina, United States

Site Status

Raleigh Medical Group

Raleigh, North Carolina, United States

Site Status

Accellacare Research of Winston Salem

Winston-Salem, North Carolina, United States

Site Status

Gastroenterology Associates of the Piedmont

Winston-Salem, North Carolina, United States

Site Status

The Center For Clinical Research

Winston-Salem, North Carolina, United States

Site Status

University Orthopedics Center

Altoona, Pennsylvania, United States

Site Status

University Orthopedics Center

Altoona, Pennsylvania, United States

Site Status

Altoona Center for Clinical Research

Duncansville, Pennsylvania, United States

Site Status

Antria Inc.

Indiana, Pennsylvania, United States

Site Status

Arthritis Group

Philadelphia, Pennsylvania, United States

Site Status

University Orthopedics Center

State College, Pennsylvania, United States

Site Status

Chan Soon-Shiong Medical Center at Windber

Windber, Pennsylvania, United States

Site Status

PCPMG Clinical Research Unit, LLC

Greenville, South Carolina, United States

Site Status

Coastal Carolina Research Center

North Charleston, South Carolina, United States

Site Status

Health Concepts

Rapid City, South Dakota, United States

Site Status

Accellacare - Knoxville

Knoxville, Tennessee, United States

Site Status

Wasatch Clinical Research

Salt Lake City, Utah, United States

Site Status

Charlottesville Medical Research Center LLC

Charlottesville, Virginia, United States

Site Status

Arthroscopic Center, Copenhagen University Hospital

Amager, , Denmark

Site Status

The Parker Institute-Frederiksberg Hospital

Frederiksberg, , Denmark

Site Status

Hospital de Cascais

Alcabideche, , Portugal

Site Status

Hospital Dos Lusiadas Lisboa

Lisbon, , Portugal

Site Status

Hospital CUF Porto

Porto, , Portugal

Site Status

Complejo Hospitalario Universitario A Coruna

A Coruña, , Spain

Site Status

Hospital Sanitas Cima

Barcelona, , Spain

Site Status

Hospital General Universitario de Elche

Elche, , Spain

Site Status

Hospital Universitaro De Elche

Elche, , Spain

Site Status

Hospital Universitario Virgen de las Nieves

Granada, , Spain

Site Status

Hospital Universitario de La Princesa

Madrid, , Spain

Site Status

Accellacare Alcobendas

Madrid, , Spain

Site Status

Hospital Universitario Virgen De La Arrixaca (Huva)

Murcia, , Spain

Site Status

Consorci Corporacio Sanitaria Parc Tauli

Sabadell, , Spain

Site Status

Institut d Investigacio i Innovacio Parc Tauli, Hospital Universitari Parc Tauli

Sabadell, , Spain

Site Status

Clinica Gaias

Santiago de Compostela, , Spain

Site Status

Complexo Hospitalario Universitario De Santiago De Compostela

Santiago de Compostela, , Spain

Site Status

Hospital Clinico Universitario De Santiago De Compostela

Santiago de Compostela, , Spain

Site Status

Hospital Quironsalud Infanta Luisa

Seville, , Spain

Site Status

Accellacare-Northamptonshire

Corby, Northamptonshire, United Kingdom

Site Status

Robert Jones & Agnes Hunt Orthopaedic Hospital - Robert Jones & Agnes Hunt Orthopaedic Hospital NHS Foundation Trust

Oswestry, Powys, United Kingdom

Site Status

Royal Orthopaedic Hospital - Nhs Foundation Trust

Birmingham, , United Kingdom

Site Status

Glasgow Royal Infirmary - Greater Glasgow Health Board

Glasgow, , United Kingdom

Site Status

Accellacare North London

Northwood, , United Kingdom

Site Status

Accellacare South London

Orpington, , United Kingdom

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States Denmark Portugal Spain United Kingdom

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2021-005020-38

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

U1111-1268-7267

Identifier Type: OTHER

Identifier Source: secondary_id

KF7039-02

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Tanezumab in Osteoarthritis of the Knee
NCT00733902 COMPLETED PHASE3